Evidence map›Paper›PMID 41789874›Full record

ArticleTurk patoloji dergisi2026

Evaluation of Morphological and Immunohistochemical Prognostic Parameters in Giant Cell Tumor of Bone.

Cem Berk Turk, Huseyin Kemal Turkoz, Omer Sofulu, Bulent Erol

Abstract read
In one paragraph

Article in Turk patoloji dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cem Berk TurkDepartment of Pathology, Marmara University School of Medicine, İSTANBUL, TÜRKİYE.
Huseyin Kemal TurkozDepartment of Pathology, Marmara University School of Medicine, İSTANBUL, TÜRKİYE.
Omer SofuluDepartment of Orthopedics and Traumatology, Marmara University School of Medicine, İSTANBUL, TÜRKİYE.
Bulent ErolDepartment of Orthopedics and Traumatology, Marmara University School of Medicine, İSTANBUL, TÜRKİYE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveGiant cell tumor of bone (GCTB) is a rarely metastasizing, locally aggressive tumor. Recurrence and metastasis in GCTB are thought to be driven by the biological behavior of the neoplastic stromal mononuclear cells. Several pathophysiological mechanisms, including expressions of p63, RANK, RANKL, and VEGF, have been proposed to influence this aggressive potential. This study aimed to identify histomorphological and immunohistochemical parameters that may predict recurrence and metastasis in patients with GCTB. MATERIAL AND

methodsThis retrospective study included 32 GCTB patients. Clinical, radiological, and pathological data were reviewed. Histomorphological features, including surgical margins, bone cortex invasion, soft tissue invasion, mitotic count, vascular invasion, percentage of spindle cell areas, and presence of tumor-associated lymphocytes (TALs), along with tumor size and demographic features, were evaluated. Tissue sections were stained with p63, RANK, RANKL, and VEGF. The relationship between these parameters and post-surgical recurrence or metastasis was analyzed.

resultsA higher percentage of spindled pattern was significantly associated with a lower frequency of recurrence. A larger tumor diameter at diagnosis was associated with the development of metastasis. Other histomorphological parameters and the expression of p63, RANK, RANKL, and VEGF were not significantly associated with recurrence or metastasis.

conclusionPercentage of spindled pattern and primary tumor diameter are potential prognostic factors for recurrence and metastasis, respectively, in GCTB.

Indexed as

Biomarkers, TumorBone NeoplasmsGiant Cell Tumor of BoneAdolescentAdultAgedFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm Recurrence, LocalPredictive Value of TestsPrognosisRANK LigandReceptor Activator of Nuclear Factor-kappa BBiomarkers, TumorRANK LigandReceptor Activator of Nuclear Factor-kappa BVascular Endothelial Growth Factor A

Identifiers

PMID41789874
PMCPMC13250933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.